Quiroz-Mercado Hugo, Martinez-Castellanos Maria A, Hernandez-Rojas Myriam L, Salazar-Teran Nelida, Chan Robinson Vernon Paul
Retina Service, Asociacion Para Evitar La Ceguera en México (APEC), Mexico City, Mexico.
Retina. 2008 Mar;28(3 Suppl):S19-25. doi: 10.1097/IAE.0b013e318159ec6b.
To evaluate the role of antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity (ROP).
In this noncomparative, prospective, interventional case series, bevacizumab was injected into the vitreous of patients with ROP in three different groups: group I, patients with stage IVa or IVb ROP who had no response to conventional treatment; group II, patients with threshold ROP who were difficult to treat with conventional therapy because of poor visualization of the retina; and group III, patients with high-risk prethreshold or threshold ROP.
Thirteen patients (18 eyes; mean age +/- SD, 4 +/- 3 months; mean follow-up, 6 months) were included in the study. We found neovascular regression in 17 eyes. One patient with stage IVa ROP had spontaneous retinal reattachment after an intravitreal injection of bevacizumab. There were no serious ocular or systemic adverse events.
The use of bevacizumab may be promising in the treatment of patients with ROP. Further studies need to be performed to determine the safety and long-term efficacy of intravitreal injection of bevacizumab, either as first-line therapy or after failure of conventional therapy.
评估玻璃体内注射贝伐单抗抗血管生成疗法在早产儿视网膜病变（ROP）治疗中的作用。
在这个非对比性、前瞻性、介入性病例系列研究中，将贝伐单抗注入三组不同的ROP患者玻璃体中：第一组，对传统治疗无反应的IVa或IVb期ROP患者；第二组，因视网膜观察不佳而难以用传统疗法治疗的阈值ROP患者；第三组，高危阈值前期或阈值ROP患者。
13例患者（18只眼；平均年龄±标准差，4±3个月；平均随访6个月）纳入研究。我们发现17只眼中新生血管消退。1例IVa期ROP患者在玻璃体内注射贝伐单抗后视网膜自发复位。未发生严重的眼部或全身不良事件。
贝伐单抗用于ROP患者的治疗可能具有前景。需要进一步研究以确定玻璃体内注射贝伐单抗作为一线治疗或在传统治疗失败后的安全性和长期疗效。
